Olstein Capital Management Portfolio in 2026: Top Holdings & Recent Changes
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Olstein Capital Management, led by veteran value investor Robert Olstein, exemplifies patient, forensic-style investing through its latest 13F filing. Their $487.6M portfolio for Q4 2025 shows measured adjustments across a broad 101-position lineup, with notable reductions in select industrials and healthcare names alongside opportunistic adds in life sciences and financial services, underscoring a strategy of trimming overvalued holdings while building into perceived bargains.
Portfolio Snapshot: Diversified Discipline with Long-Term Conviction
Portfolio Highlights (Q4 2025): - Market Value: $487.6M - Top 10 Holdings: 19.1% - Portfolio Size: 101 -2 - Average Holding Period: 24 quarters - Turnover: 7.9%
Olstein Capital Management's Q4 2025 portfolio maintains its hallmark diversification, with the top 10 holdings representing just 19.1% of the total—a stark contrast to ultra-concentrated superinvestors. This structure reflects Robert Olstein's philosophy of spreading risk across numerous undervalued opportunities while keeping turnover low at 7.9%, signaling confidence in core positions held for an average of 24 quarters (six years). The slight reduction in portfolio size to 101 positions -2 suggests disciplined pruning of underperformers.
The low concentration in top holdings enables flexibility to navigate market volatility, as seen in the mix of adds and reduces among leaders. With such a broad base, Olstein avoids over-reliance on any single name, prioritizing quality balance sheets and free cash flow generation in overlooked sectors. Tracking via ValueSense's Olstein tracker reveals this as a resilient approach for uncertain times, blending patience with tactical shifts.
This setup also highlights Olstein's forensic accounting focus—identifying "quality of earnings" discrepancies that others miss—allowing the fund to hold steady through cycles while opportunistically reweighting.
Key Positions: Surgical Trims and Value Adds Across Sectors
Recent moves in Olstein Capital Management's portfolio reveal a pattern of reducing top-weighted names showing signs of overvaluation while adding to promising turnarounds, starting with the largest holding The Walt Disney Company (DIS) at 2.5%, which saw a modest "Reduce 1.04%". Significant trims continued with Sensata Technologies Holding plc (ST) (1.9%, "Reduce 17.92%") and Schlumberger Limited (SLB) (1.7%, "Reduce 13.04%"), alongside healthcare giant Becton, Dickinson and Company (BDX) (1.7%, "Reduce 18.27%"), indicating profit-taking in industrials and medtech amid valuation concerns.
On the buy side, the firm boosted Avantor, Inc. (AVTR) (1.9%, "Add 3.02%"), ABM Industries Incorporated (ABM) (1.8%, "Add 1.14%"), and International Flavors & Fragrances Inc. (IFF) (1.8%, "Add 1.60%"), with further conviction in Fidelity National Information Services, Inc. (FIS) ("Add 7.50%" at 1.7%), Baxter International Inc. (BAX) ("Add 14.25%" at 1.6%), and Mohawk Industries, Inc. (MHK) ("Add 23.87%" at 1.5%), signaling bets on healthcare and materials recovery.
Stable anchors include LKQ Corporation (LKQ) (2.0%, "No change"), Vontier Corporation (VNT) (2.0%, "No change"), and Omnicom Group Inc. (OMC) (1.8%, "No change"), providing continuity in auto parts, industrials, and advertising. These adjustments across 15 key names blend defensive industrials with cyclical healthcare and fintech plays, maintaining balance in a diversified framework.
What the Portfolio Reveals: Value Discipline in Action
Olstein Capital Management's Q4 moves underscore a quality-over-quantity strategy, favoring companies with strong earnings power and clean accounting over high-growth hype. The heavy reductions in ST, SLB, and BDX suggest vigilance against deteriorating fundamentals, while adds to AVTR, BAX, and MHK target undervalued life sciences and industrials with turnaround potential.
Sector focus spans industrials (LKQ, VNT, ABM), healthcare (AVTR, BAX, BDX, IFF), energy services (SLB), and fintech (FIS), with U.S.-centric geographic concentration minimizing international risks. Low turnover and a 24-quarter hold period emphasize dividend sustainability and free cash flow, avoiding yield traps.
Risk management shines through diversification—101 positions limit single-stock blowups—paired with position sizing under 3%, enabling nimble responses to earnings surprises that Olstein's forensic analysis excels at spotting.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Portfolio Concentration Analysis
| Position | Value | % of Portfolio | Recent Change |
|---|---|---|---|
| The Walt Disney Company (DIS) | $12.3M | 2.5% | Reduce 1.04% |
| LKQ Corporation (LKQ) | $9,612.0K | 2.0% | No change |
| Vontier Corporation (VNT) | $9,518.0K | 2.0% | No change |
| Sensata Technologies Holding plc (ST) | $9,454.0K | 1.9% | Reduce 17.92% |
| Avantor, Inc. (AVTR) | $9,374.0K | 1.9% | Add 3.02% |
| ABM Industries Incorporated (ABM) | $8,941.0K | 1.8% | Add 1.14% |
| Omnicom Group Inc. (OMC) | $8,883.0K | 1.8% | No change |
| International Flavors & Fragrances Inc. (IFF) | $8,559.0K | 1.8% | Add 1.60% |
| Schlumberger Limited (SLB) | $8,444.0K | 1.7% | Reduce 13.04% |
| Becton, Dickinson and Company (BDX) | $8,248.0K | 1.7% | Reduce 18.27% |
This table illustrates Olstein Capital Management's intentionally low concentration, with no position exceeding 2.5% and the top 10 aggregating just 19.1%—a deliberate choice for risk control in a 101-stock portfolio. The mix of "No change" in steady names like LKQ and VNT contrasts with aggressive trims (e.g., 18.27% in BDX, 17.92% in ST), freeing capital for adds like AVTR and IFF, reflecting data-driven rebalancing.
Such modest sizing allows the fund to weather sector rotations without forced selling, while the -2 position trim signals ongoing portfolio hygiene. This structure amplifies the power of long-term holds (24 quarters average) in quality names, prioritizing capital preservation over home runs.
Investment Lessons from Olstein Capital Management's Approach
Olstein Capital Management's Q4 2025 portfolio demonstrates timeless value principles tailored to Robert Olstein's forensic style:
- Forensic earnings analysis trumps headlines: Deep dives into quality of earnings explain bold trims like ST -17.92% and adds to MHK +23.87%, spotting discrepancies others miss.
- Diversification with conviction sizing: 101 positions cap risk at ~2% per top holding, enabling patience in 24-quarter averages without overexposure.
- Trim winners, buy distress selectively: Reduces in DIS and SLB fund opportunistic healthcare adds (BAX +14.25%, AVTR +3.02%), balancing cycle plays.
- Low turnover preserves compounding: 7.9% rate underscores holding winners like LKQ "No change," avoiding tax drag and transaction costs.
- U.S.-centric industrials and healthcare focus: Prioritizes tangible assets with free cash flow, sidestepping speculative growth.
Looking Ahead: What Comes Next?
Olstein Capital Management enters 2026 with a leaner 101-position portfolio and low 7.9% turnover, positioning for opportunistic deployment amid potential economic softening. The trims in energy (SLB) and medtech (BDX) have likely built cash flexibility for deeper value in cyclicals like MHK or FIS, especially if rate cuts boost industrials.
Market conditions favor Olstein's moat: healthcare adds (AVTR, BAX) set up for biotech rebound, while stable names (LKQ, VNT) hedge slowdowns. Watch for earnings-driven tweaks in Q1 2026 filings—ValueSense's Olstein tracker will flag shifts, given 13F's 45-day lag. Current balance sheet focus equips the fund for volatility, targeting 8-10% annual returns through undervalued compounding.
FAQ about Olstein Capital Management Portfolio
Q: What were the biggest changes in Olstein Capital Management's Q4 2025 13F filing?
A: Key reduces included BDX -18.27%, ST -17.92%, and SLB -13.04%, while standout adds were MHK +23.87%, BAX +14.25%, and FIS +7.50%, reflecting value rotation.
Q: Why does Olstein maintain such low concentration in top holdings?
A: With top 10 at just 19.1% across 101 positions, the strategy diversifies risk while allowing forensic picks like AVTR and IFF to compound, emphasizing earnings quality over big bets.
Q: What sectors dominate Olstein Capital Management's portfolio?
A: Industrials (LKQ, VNT, ABM), healthcare/life sciences (AVTR, BAX, BDX, IFF), and energy services (SLB) lead, with fintech (FIS) exposure—U.S.-focused for stability and cash flow.
Q: How can I track Olstein Capital Management's future moves?
A: Use ValueSense's superinvestor tracker at https://valuesense.io/superinvestors/olstein-capital for real-time 13F updates, historical changes, and visualizations—remember the 45-day SEC filing lag means checking quarterly.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2026)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!